Amica Retiree Medical Trust Acquires Shares of 129 Synopsys, Inc. $SNPS

Amica Retiree Medical Trust acquired a new stake in Synopsys, Inc. (NASDAQ:SNPS) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 129 shares of the semiconductor company’s stock, valued at approximately $66,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of SNPS. Brighton Jones LLC lifted its position in Synopsys by 5.7% in the fourth quarter. Brighton Jones LLC now owns 921 shares of the semiconductor company’s stock worth $447,000 after buying an additional 50 shares during the last quarter. Valeo Financial Advisors LLC raised its stake in shares of Synopsys by 6.3% in the first quarter. Valeo Financial Advisors LLC now owns 570 shares of the semiconductor company’s stock valued at $244,000 after acquiring an additional 34 shares during the period. LBP AM SA bought a new stake in shares of Synopsys in the 1st quarter worth about $318,000. Allworth Financial LP lifted its holdings in shares of Synopsys by 3.1% in the 1st quarter. Allworth Financial LP now owns 2,499 shares of the semiconductor company’s stock worth $1,097,000 after acquiring an additional 74 shares during the last quarter. Finally, Alps Advisors Inc. boosted its stake in shares of Synopsys by 45.8% during the 1st quarter. Alps Advisors Inc. now owns 4,058 shares of the semiconductor company’s stock worth $1,740,000 after purchasing an additional 1,275 shares during the period. Hedge funds and other institutional investors own 85.47% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wells Fargo & Company reduced their price objective on shares of Synopsys from $630.00 to $550.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 10th. Robert W. Baird restated a “neutral” rating and set a $535.00 target price (down previously from $670.00) on shares of Synopsys in a research report on Wednesday, September 10th. The Goldman Sachs Group cut their target price on Synopsys from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Wednesday, September 10th. Piper Sandler decreased their price target on Synopsys from $660.00 to $630.00 and set an “overweight” rating for the company in a research note on Wednesday, September 10th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Synopsys in a report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $569.67.

Synopsys Stock Performance

SNPS stock opened at $393.43 on Friday. Synopsys, Inc. has a one year low of $365.74 and a one year high of $651.73. The firm has a market cap of $73.08 billion, a price-to-earnings ratio of 30.88, a PEG ratio of 5.02 and a beta of 1.10. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.51 and a current ratio of 1.62. The firm has a 50-day simple moving average of $475.14 and a two-hundred day simple moving average of $514.87.

Synopsys (NASDAQ:SNPS) last posted its quarterly earnings data on Tuesday, September 9th. The semiconductor company reported $2.30 EPS for the quarter, missing the consensus estimate of $3.75 by ($1.45). The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.77 billion. Synopsys had a return on equity of 10.82% and a net margin of 31.04%.The company’s revenue was up 14.0% compared to the same quarter last year. During the same quarter last year, the firm earned $3.43 EPS. Synopsys has set its FY 2025 guidance at 12.760-12.800 EPS. Q4 2025 guidance at 2.760-2.80 EPS. On average, equities analysts forecast that Synopsys, Inc. will post 10.64 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Sudhindra Kankanwadi sold 9,873 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $500.90, for a total value of $4,945,385.70. Following the completion of the sale, the chief accounting officer owned 20,520 shares of the company’s stock, valued at $10,278,468. This trade represents a 32.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Shelagh Glaser sold 3,655 shares of the company’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $609.77, for a total value of $2,228,709.35. Following the transaction, the chief financial officer directly owned 15,317 shares in the company, valued at $9,339,847.09. This represents a 19.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 30,894 shares of company stock worth $16,760,783. 0.62% of the stock is currently owned by company insiders.

About Synopsys

Synopsys, Inc provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.